Abcentra LLC

Abcentra LLC

Abcentra is a clinical stage biopharmaceutical company that is working to improve treatment options for patients with coronary artery disease. Abcentra's first-in-class monoclonal antibody against oxidized LDL, orticumab, is a plaque-targeted anti-inflammatory therapy that is being developed for secondary prevention of cardiac events after acute coronary syndrome (currently in phase 2). By inhibiting pro-inflammatory macrophages within plaques, orticumab has the potential to reduce cardiovascula